Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
- 1 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 5 (9), 2160-2169
- https://doi.org/10.1111/j.1743-6109.2008.00935.x
Abstract
With once-daily administration of tadalafil, dosing and sexual activity would no longer need to be temporally linked for patients with erectile dysfunction (ED). To evaluate long-term safety and efficacy of tadalafil 5 mg dosed once daily for the treatment of ED. Patients > or = 18 years of age with ED of any functional severity or etiology received tadalafil 5 mg once daily for 1 (N = 234) or 2 (N = 238) years during the open-label extensions of two previously reported studies. Patients who completed the 1-year open-label extension concluded with a 4-week ED treatment-free period. Baseline was defined as prior to receiving any study drug. Safety measures included adverse events, electrocardiograms, and clinical laboratory measures. Efficacy measures included the International Index of Erectile Function (IIEF)-Erectile Function (-EF), -Intercourse Satisfaction (-IS), and -Overall Satisfaction (-OS) domain scores, and the Global Assessment Questions (GAQ1: improved erections; GAQ2: improved ability to engage in sexual activity). Overall, 208/234 (88.9%) and 139/238 (58.4%) patients completed the 1- and 2-year open-label extensions, respectively. No study drug-related serious adverse events were observed. Treatment-emergent adverse events observed in > or = 5% of the patients during the first year of either open-label extension were dyspepsia, headache, back pain, and influenza. No clinically meaningful abnormalities associated with tadalafil were observed for electrocardiograms or clinical laboratory measures. Mean IIEF domain scores improved from baseline to the conclusions of the 1- and 2-year open-label extensions, respectively: -EF, +10.4 and +10.8; -IS, +4.0 and +3.7; and -OS, +3.0 and +3.2. At the conclusion of the 2-year open-label extension, 95.7% and 92.1% of the patients reported positive responses to GAQ1 and GAQ2, respectively. In these long-term, open-label, once-daily dosing studies, tadalafil 5 mg was well tolerated and effective, making it a viable alternative to the current on-demand dosing of tadalafil for men with ED.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunctionDiabetic Medicine, 2008
- Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2006
- Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the USInternational Journal Of Impotence Research, 2006
- Cardiovascular Safety Update of Tadalafil: Retrospective Analysis of Data from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil With As Needed, Three Times-per-Week or Once-a-Day DosingThe American Journal of Cardiology, 2006
- Phosphodiesterase Type 5 is Not Upregulated by Tadalafil in Cultures of Human Penile CellsThe Journal of Sexual Medicine, 2006
- Tadalafil Improved Erectile Function at Twenty‐Four and Thirty‐Six Hours After Dosing in Men With Erectile Dysfunction: US TrialJournal of Andrology, 2005
- Comparison of Efficacy, Safety, and Tolerability of On-Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile DysfunctionThe Journal of Sexual Medicine, 2005
- Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to On-Demand TadalafilThe Journal of Sexual Medicine, 2004
- Long-Term Safety and Tolerability of Tadalafil in the Treatment of Erectile DysfunctionEuropean Urology, 2004
- Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panelThe American Journal of Cardiology, 2000